Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy by Pedersen, Kjetil Boye et al.
1840
Introduction
Colorectal cancer (CRC) is one of the most common 
cancer types worldwide and a major cause of cancer death. 
The prognosis of patients with CRC is highly dependent 
on the tumor stage at diagnosis. Five- year overall survival 
for patients with stage I disease is approximately 90%, 
decreasing to about 10% for stage IV patients [1]. In 
curatively resected CRC, certain stage- specific factors pro-
vide additional prognostic value, such as tumor 
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Abstract
Current clinical algorithms are unable to precisely predict which colorectal cancer 
patients would benefit from adjuvant chemotherapy, and there is a need for 
novel biomarkers to improve the selection of patients. The metastasis- promoting 
protein S100A4 predicts poor outcome in colorectal cancer, but whether it could 
be used to guide clinical decision making remains to be resolved. S100A4 
 expression was analyzed by immunohistochemistry in primary colorectal carci-
nomas from a consecutively collected, population- representative cohort and a 
randomized phase III study on adjuvant 5- fluorouracil/levamisole. Sensitivity to 
treatment with 5- fluorouracil in S100A4 knockdown cells was investigated using 
2D and 3D cell culture assays. Strong nuclear expression of S100A4 was detected 
in 19% and 23% of the tumors in the two study cohorts, respectively. In both 
cohorts, nuclear immunoreactivity was associated with reduced relapse- free 
(P < 0.001 and P = 0.010) and overall survival (P = 0.046 and P = 0.006) in 
univariate analysis. In multivariate analysis, nuclear S100A4 was a predictor of 
poor relapse- free survival in the consecutive series (P = 0.002; HR 1.9), but 
not in the randomized study. Sensitivity to treatment with 5- fluorouracil was 
not affected by S100A4 expression in in vitro cell culture assays, and there was 
no indication from subgroup analyses in the randomized study that S100A4 
expression was associated with increased benefit of adjuvant treatment with 
5- fluorouracil/levamisole. The present study confirms that nuclear S100A4 
 expression is a negative prognostic biomarker in colorectal cancer, but the  clinical 
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perforation, T4 status, and number of examined lymph 
nodes in stage II and the number of involved lymph 
nodes in stage III [1, 2]. Still, the biological behavior of 
the tumors within each tumor stage varies considerably, 
and a more precise prediction of patient outcome could 
lead to better treatment decisions.
Adjuvant fluoropyrimidine- based chemotherapy is rou-
tinely offered to colon cancer patients in TNM stage III 
and to selected high- risk stage II patients. The absolute 
survival advantage in stage III is approximately 10–15%, 
whereas a clear difference in overall survival has not been 
shown in stage II [2]. Consequently, the majority of patients 
receiving adjuvant chemotherapy do not benefit from the 
treatment, either because they would have been cured by 
surgery alone or because they nevertheless experience disease 
recurrence. Thus, new prognostic and predictive factors 
to improve the selection of patients for adjuvant treatment 
would be of great clinical importance.
S100A4 is a small, multifunctional, Ca2+- binding protein 
with the ability to promote invasion and metastasis in 
several cancer types [3]. In CRC, S100A4 is overexpressed 
compared to normal mucosa and adenomas, and higher 
expression has been observed in liver metastases than in 
primary tumors [4, 5]. Several studies have shown that 
S100A4 is a strong predictor of poor survival in patients 
undergoing curatively intended surgery [6–12]. The protein 
is localized in the nucleus and the cytoplasm, and nuclear 
expression seems to be the best prognostic parameter [6, 
13]. Suggested biological functions of nuclear S100A4 
include interaction with p53 and inhibition of p53- 
dependent cell cycle arrest and apoptosis [14] and colo-
calization with centrosomes and regulation of the G2/M 
phase [15], but the phenotypic outcome of nuclear S100A4 
expression is in general incompletely characterized. Even 
though there is a large body of evidence documenting 
the prognostic impact of S100A4 in CRC, it remains to 
be resolved whether immunohistochemical staining for 
S100A4 could be an adjunct to other biomarkers in rou-
tine clinical practice. Here, we have investigated the clinical 
impact of S100A4 expression in a large, unselected, 
population- representative cohort and in a randomized 
study on adjuvant chemotherapy in stage II and III patients.
Materials and Methods
Patient cohorts
Study cohort 1 is a population- representative consecutive 
series of CRC patients from Oslo University Hospital Aker, 
and has been previously reported [16–18]. Briefly, all 
patients with CRC from 1993 to 2003 were registered 
and clinical data were prospectively recorded. Of the 1290 
patients included, 929 underwent a major resection and 
had tumor samples available for tissue microarray (TMA) 
construction [17]. Colon cancer patients ≤75 years of age 
and all rectal cancer patients who underwent curative 
surgery entered a 5- year follow- up program as described 
previously [18]. Study cohort 2 consists of CRC patients 
included in a Norwegian randomized phase III study on 
adjuvant 5- fluorouracil/levamisole [19]. Four hundred 
twenty- five patients who had a radical resection for an 
adenocarcinoma of the colon or rectum were included 
in the study between January 1993 and October 1996. 
Of the 412 evaluable patients, 206 patients were rand-
omized to 49 weeks of 5- fluorouracil and levamisole and 
206 patients to no further treatment after radical surgery. 
Both studies were approved by the Regional Ethics’ 
Committees and written informed consent was obtained.
Immunohistochemistry
The construction of TMAs has been described previously 
[17, 20]. Sections from the TMAs were immunostained 
using the Dako EnVision Flex+ detections system (Dako, 
Glostrup, Denmark) as described previously [21]. The 
monoclonal anti- S100A4 antibody 20.1 in a final concen-
tration of 1.8 μg/mL was used [22]. Negative controls 
included replacement of the primary antibody with mouse 
myeloma protein of the same subclass and concentration, 
and preabsorption experiments using recombinant S100A4. 
Sections from CRC tumor tissue known to express high 
levels of S100A4 were used as positive controls.
Evaluation of immunohistochemistry
For study cohort 1, S100A4 immunoreactivity was evalu-
ated independently by two of the authors (K. B. and K. 
F.), and nuclear and cytoplasmic staining were registered 
as separate variables. Staining intensity was scored as nega-
tive, weak, moderate, and strong. The number of positive 
tumor cells was estimated and grouped as follows: 0 (0%), 
1 (<1%), 2 (1–10%), 3 (11–33%), 4 (34–66%), and 5 
(>66%). Discrepant results were reviewed in common and 
consensus was reached. For all analyses, negative/weak and 
moderate/strong staining intensity were grouped and con-
sidered negative and positive, respectively, and only cases 
with moderate or strong intensity (defined as positive) 
were classified with respect to the fraction of positive tumor 
cells. Based on the number of cases in the percentage 
groups, group 1–4 (1–66%) was considered moderately 
positive and group 5 (>66%) strongly positive. For study 
cohort 2, immunoreactivity was scored as negative, moder-
ate, and strong according to the criteria defined through 
analysis of cohort 1, and dichotomized as negative/moderate 
and strong for all analyses. Evaluation was performed by 
two independent observers (H. J. and J. M. N.).
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Statistical analysis
Associations between S100A4 staining and clinicopatho-
logical variables were tested using Fisher’s exact test, 
linear- by- linear association chi- square test, or independent 
samples t test as appropriate. Univariate survival analysis 
was performed according to the Kaplan–Meier method, 
and survival was compared using the log rank test. 
Multivariate analysis was conducted using the Cox pro-
portional hazards regression model with backward, stepwise 
elimination of variables. The time from surgery (cohort 
1) or randomization (cohort 2) to diagnosis of distant 
or local recurrence was recorded as relapse- free survival. 
Patients were censored at death of any cause or when 
lost to follow- up. Overall survival was defined as the time 
from surgery or randomization to death of any cause. 
Median follow- up for overall survival for patients still 
alive was 9.7 years for cohort 1 (range 5.2–17.3) and 
7.6 years (range 4.9–11.0) for cohort 2. Data analysis was 
performed using SPSS version 21.0 (SPSS Inc., Chicago, 
IL, USA). All P values are two- tailed and considered sig-
nificant when P < 0.05.
Cell culture and treatment
The human CRC cell lines HCT116 and SW620 were 
obtained from American Type Cell Collection (ATCC; 
Manassas, VA). Cells were cultured in RPMI 1640 (Lonza, 
Basel, Switzerland) supplemented with 8% (v/v) fetal bovine 
serum (FBS; Life Technologies, Carlsbad, CA), 1% (v/v) 
Hepes buffer (Lonza), and 1% (v/v) Glutamax (Life 
Technologies). The generation of stably transduced cells 
expressing shRNA against S100A4 (shA4) has been 
described previously [15]. Cell line identity was validated 
by short tandem repeat analysis using the STR PowerPlex16 
System (Promega, Fitchburg, WI), and all cell cultures 
were routinely tested for Mycoplasma infection. Prior to 
experiments, subconfluent cells were trypsinated (Lonza), 
seeded in multiwell dishes or cell culture flasks, and allowed 
to adhere overnight. The cell culture medium was then 
removed and replaced with fresh culture medium with 
or without 5- fluorouracil (5FU; Hospira, Lake Fores, IL) 
as indicated. The cells were incubated for 4 h before the 
drug was removed, fresh medium was added to each well, 
and cells were further incubated for the time periods 
indicated before harvesting.
Cell viability
Cells were seeded at a density of 1.5 × 104 (HCT116) 
or 2.25 × 104 (SW620) cells/cm2 in 96- well plates, treated 
as described earlier, and incubated for 72 h after removal 
of drug. Cell viability was measured using CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (Promega) 
according to the manufacturer’s instructions.
Clonogenic survival
One hundred cells per well were seeded in a volume of 
2 mL in 6- well plates and treated as described earlier. 
The plates were incubated for about 1 week until colonies 
of appropriate size were detectable by visual inspection. 
The colonies were fixed using ice- cold methanol for 1 min 
at room temperature and stained with 0.05% crystal violet 
dye (Apotekproduksjon, Oslo, Norway). Colonies contain-
ing ≥50 tumor cells were then counted manually at a 
Gerber Counter (Gerber Scientific Products, Tolland, CT).
Spheroid assay
The protocols for forming spheroids and measuring cell 
viability by calculated spheroid volume were adapted from 
Vinci and coworkers [23]. Briefly, 1000 cells per well 
were seeded in 96- well, ultralow attachment plates (Costar, 
Washington, DC) and incubated for 72 h. The spheroids 
were then treated with chemotherapy as described earlier. 
The spheroids were photographed using an IX81- motorized 
inverted microscope (Olympus, Shinjuku, Tokyo, Japan) 
96 h after treatment, and the software Cell^P (Olympus) 
was used to calculate the spheroid volume. The average 
radius of the spheroids was calculated, and spheroid vol-
umes computed with the formula V = 4/3πr3, based on 
the assumption that the spheroids were approximately 
spherical.
Protein analysis




The clinical and histopathological data of the study cohort 
are presented in Table 1. Median age was 73 years (range 
29–94). Of the 929 tumor samples present on the TMA, 
146 cases were not evaluable for technical reasons or 
because no tumor tissue was present, leaving 783 cases 
available for S100A4 analysis. In 64 cases there were dis-
crepant results in scoring of nuclear immunoreactivity 
between the two observers, resulting in a κ value of 0.73 
(classified as “substantial agreement”). Nineteen percent 
of the tumors displayed strong nuclear S100A4 expression, 
while 44% showed strong cytoplasmic staining (Table 2; 
complete scoring results are presented in Table S1). 
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Representative photomicrographs of immunohistochemical 
staining of S100A4 are presented in Figure 1. Associations 
between S100A4 expression and clinical and histopatho-
logical characteristics are shown in Table S2. There was 
a weak relationship between S100A4 nuclear staining and 
male gender, advanced T stage, and poor tumor differ-
entiation. No other statistically significant associations were 
discovered.
For the survival analyses, patients with TNM stage IV 
(n = 148), unknown TNM stage (n = 1), or R1/R2 
resection (n = 33) were excluded, resulting in an outcome 
cohort of 601 patients. Of these, 116 (19%) experienced 
a recurrence during follow- up. Ninety patients were reg-
istered with distant metastasis, 12 with isolated local recur-
rence, and 14 with local and distant recurrence. Strong 
nuclear expression of S100A4 was a powerful prognostic 
factor for reduced relapse- free survival in univariate analy-
sis, with an estimated 5- year survival of 61% compared 
to 80% for negative and moderate staining (P < 0.001; 
Fig. 2). Patients with negative and moderate S100A4 
expression had a similar outcome (Fig. S1A; P = 0.20 in 
pairwise comparison), thus for all analyses expression was 
dichotomized into negative/moderate and strong. Overall 
survival was also significantly poorer for patients with 
S100A4- positive tumors (P = 0.046; Fig. 2B). In subgroup 
analyses, S100A4 was of prognostic significance in TNM 
stages II and III (Fig. S1C and D) and for patients with 
colon cancer and rectal cancer when analyzed separately 
(Fig. S1E and F). Cytoplasmic expression was not associ-
ated with relapse- free or overall survival (Fig. S2A and 
B). In multivariate analysis, nuclear S100A4 was signifi-
cantly associated with relapse- free survival (P = 0.002; HR 
1.9; 95% CI: 1.3–2.9; Table 3). TNM stage and age were 
also included in the final model, and the variables entered 
were S100A4, TNM stage, age, gender, tumor localization 
(colon vs. rectum), and differentiation. Taken together, 
these results convincingly confirm that nuclear expression 
of S100A4 is a strong prognostic factor in CRC, and that 
the prognostic significance is retained across tumor stage 
and localization.
Study cohort 2
To examine the prognostic impact of S100A4 in patients 
receiving adjuvant treatment, we investigated the expres-
sion in tumor samples from patients included in a phase 
III randomized study that compared surgery alone with 
surgery and 5- fluorouracil/levamisole in stage II or III 
colon and rectal cancer patients [19]. Samples for TMA 
construction were available for 409 of the 412 patients 
[20]. In 39 cases, S100A4 staining was not technically 
successful, leaving a study population of 370 patients. 
The clinical and histopathological characteristics are pre-
sented in Table 1. Median age was 63 years (range 28–75).
S100A4 expression was dichotomized as strongly posi-
tive or negative/moderate according to the criteria defined 
for cohort 1. In 14 of 370 cases, the observers were not 
in agreement with the scoring of nuclear S100A4 staining, 
resulting in a κ value of 0.89 (classified as “almost perfect 
agreement”). Eighty- four (23%) of 370 samples were clas-
sified as strongly positive for nuclear and cytoplasmic 
immunoreactivity (Table 2), of which 73 cases showed 
strong staining in both subcellular compartments. 
Table 1. Baseline clinical and histopathological data of study cohorts 1 
and 2.
Parameters
Study cohort 11 Study cohort 21
N % N %
Gender
 Female 415 53 179 48
 Male 368 47 191 52
TNM stage
 I 119 15 0 0
 II 317 41 219 59
 III 198 25 151 41
 IV 148 19 0 0
pT
 1 30 4 3 1
 2 111 14 28 8
 3 561 72 316 85
 4 81 10 23 6
pN
 0 483 62 219 59
 1 212 27 100 27
 2 81 10 51 14
 ND 7 0
Differentiation
 Well/moderate 663 88 306 84
 Poor 93 12 58 16
 ND 27 6
Tumor localization
 Colon 589 75 261 71
 Rectum 189 24 109 29
 Synchronous 5 1 0 0
ND, not determined.
1A total of 783 and 370 patients were examined.
Table 2. Immunohistochemical expression of S100A4 in study cohorts 
1 and 2.
Nuclear staining1 Cytoplasmic staining1
Study cohort 1
 Negative/moderate 635 (81) 439 (56)
 Strong 148 (19) 344 (44)
Study cohort 2
 Negative/moderate 286 (77) 286 (77)
 Strong 84 (23) 84 (23)
1The number of cases and percentages (in parentheses) are shown.
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Associations between S100A4 expression and clinicopatho-
logical parameters are shown in Table S3. Thirty- one 
percent of stage III tumors displayed S100A4 nuclear 
expression compared to only 16% for stage II (Table S3; 
P = 0.001). No other statistically significant associations 
were found.
One hundred thirty- two of the 370 patients suffered 
from disease relapse (local recurrence and/or distant metas-
tasis) during follow- up, and 148 were registered as dead. 
In univariate analyses, S100A4 nuclear expression was 
associated with reduced relapse- free survival (P = 0.010; 
Fig. 2C) and overall survival (P = 0.006; Fig. 2D), and 
cytoplasmic expression was also a predictor of poor out-
come (Fig. S2C and D). Nuclear S100A4 was, however, 
not significantly associated with relapse- free survival in 
multivariate analysis including the covariates S100A4, gen-
der, age, TNM stage, tumor localization (colon vs. rectum), 
and tumor differentiation (Table 3).
S100A4 expression and adjuvant treatment
To analyze the implication of S100A4 expression in patients 
receiving adjuvant treatment, we first considered TNM 
stage III colon cancer patients, as this was the only 
Figure 1. Representative photomicrographs showing immunohistochemical staining of S100A4. (A) No immunoreactivity in the cytoplasm and 
nucleus. (B) Moderately positive nuclear and cytoplasmic staining. (C) Strong nuclear and cytoplasmic staining.
A B C
Figure 2. Kaplan–Meier survival curves based on the expression of nuclear S100A4. (A) Relapse- free survival and (B) overall survival in study cohort 1. 
(C) Relapse- free survival and (D) overall survival in study cohort 2.
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subgroup with a survival benefit of adjuvant chemotherapy 
in this study [19]. Adjuvant treatment seemed to be of 
benefit for both S100A4- positive and - negative patients 
(Fig. S3A and B), even if the differences were not statisti-
cally significant due to a relatively small number of patients. 
To further explore whether S100A4 expression in tumor 
cells could affect sensitivity to 5- fluorouracil, cell culture 
experiments using CRC cell lines with manipulated levels 
of S100A4 were performed. The cell lines HCT116 and 
SW620 express high amounts of S100A4, and S100A4 
knockdown cells were generated by stable lentiviral trans-
duction with S100A4 shRNA (Fig. 3A). When exposed 
to increasing concentrations of 5- fluorouracil, HCT116 
was clearly the more sensitive cell line, but sensitivity was 
independent of S100A4 expression in both cell lines (Fig. 3B 
and C). Additional experiments were performed in HCT116 
cells using the clonogenic survival assay and in three- 
dimensional spheroid cell cultures, but S100A4 expression 
did not influence the sensitivity to 5- fluorouracil in any 
of the investigated experimental conditions (Fig. 3 D and 
E).
Furthermore, we asked if the prognostic value of S100A4 
could be used to select colon cancer patients for adjuvant 
treatment, either to identify stage II patients who would 
benefit or to identify stage III patients with an excellent 
prognosis who might not profit from adjuvant chemo-
therapy. S100A4- negative stage III colon cancer patients 
had an estimated 3- year relapse- free survival of 66% and 
55% in cohorts 1 and 2, respectively, implying that these 
patients likely would benefit from additional treatment. 
In stage II tumors of the colon, nuclear expression was 
a negative prognostic marker in cohort 1 (Fig. S3C), but 
not in the surgery- only group in cohort 2 (Fig. S3D). 
Nevertheless, S100A4- positive stage II colon cancer patients 
randomized to adjuvant 5- fluorouracil and levamisole had 
a poor outcome with an estimated 3- year relapse- free 
survival of 71% compared to 88% for S100A4- negative 
patients (Fig. S3E).
Discussion
The findings in our study were based on two patient 
cohorts. The first is an unselected, consecutive series from 
one Norwegian hospital from 1993 to 2003 [18]. The 
series can be considered population- based because patients 
were consecutively enrolled from a geographically defined 
catchment area, and because the completeness of the 
inclusion has been verified against the Cancer Registry 
of Norway. Less than 10% of the patients received adju-
vant treatment [18], and the cohort is thus suited for 
investigation of prognostic markers. Furthermore, the 
cohort size is relatively large and allows relevant subgroup 
analyses, such as stratification based on TNM stage and 
tumor localization. The second cohort is a randomized, 
multicentre trial on adjuvant chemotherapy in stage II 
and III patients included between 1993 and 1996 [19]. 
Tumor samples for TMA construction were available from 
nearly all patients, and the cohort is thus well fitted for 
studies on prognostic and predictive tissue biomarkers in 
patients receiving adjuvant fluoropyrimidine- based chemo-
therapy. For this purpose, it is a great advantage that 
one randomization arm was surgery alone, allowing the 
comparison between patients receiving or not receiving 
adjuvant treatment.
We found that 19% and 23% of the cases had strong 
nuclear staining in cohorts 1 and 2, respectively, whereas 
strong cytoplasmic staining was observed in 44% and 23% 
of the tumors.
The reason for the difference in cytoplasmic expression 
is uncertain. Clinical and demographic variables were 
similar in the two cohorts aside from the stage distribu-
tion, but this could not explain the discrepancy as the 
percentage of tumors with cytoplasmic staining in stages 
II and III in cohort 1 was 46%. Different observers evalu-
ated the slides in the two series, and especially intensity 
scoring is a subjective judgment. However, the frequency 
of nuclear staining was comparable, indicating that the 
interobserver variability is reasonably low. Differences in 
TMA construction between the two cohorts might also 
contribute as one 0.6 mm core per tumor was used for 
study cohort 1 compared to one to three cylinders for 
cohort 2. The percentage of S100A4- positive tumors in 
previous studies in CRC has varied considerably due to 
different scoring algorithms and cutoffs, patient selection, 
and technical reasons (e.g., antibodies used and TMAs 
vs. whole sections). Here, we used a cutoff for strong 
staining of 66%, which is similar to the two other large 
Table 3. Multivariate Cox regression analysis of relapse- free survival.1
P value Hazard ratio 95% CI
Study cohort 1
 S100A4 0.002
  Negative Ref
  Positive 1.9 1.3–2.9
 TNM stage <0.001
  I Ref
  II 2.1 1.0–4.2
  III 5.3 2.6–10.7
 Age 0.02 1.02 1.00–1.03
Study cohort 2
 TNM stage <0.001
  II Ref
  III 4.1 2.8–5.9
 Tumor differentiation 0.03
  High/moderate Ref
  Low 1.6 1.0–2.5
1All parameters included in the final models are shown.
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series where TMAs were employed [7, 9]. Gongoll and 
coworkers used 50% as a cutoff, but did not evaluate 
cytoplasmic and nuclear staining separately, whereas Kho 
et al. applied 50–70% based on the optimal dichotomy 
for prognostic significance. In our previous study using 
whole sections a cutoff of 1% was used [6], but the fre-
quency of positive cells might not be comparable between 
TMAs and whole sections since a large degree of intra-
tumoral heterogeneity of S100A4 expression is observed 
in CRC [5, 9].
Nuclear expression was a stronger predictor of poor 
prognosis than cytoplasmic expression in cohort 1, sup-
porting the findings in our previous study [6]. In cohort 
2, S100A4 expression in both subcellular localizations had 
prognostic significance, which might reflect the large degree 
of overlap between cytoplasmic and nuclear staining in 
this study, as only 22 of 370 tumors displayed strong 
expression exclusively for either compartment. Only two 
previous investigations on CRC have recorded nuclear 
and cytoplasmic S100A4 as separate variables [6, 9], and 
nuclear expression was a predictor of inferior outcome 
in both studies, albeit not after adjustment for other 
prognostic variables in the Australian series. Despite dif-
ferences between studies, a high level of S100A4 expression 
either in the nucleus or cytoplasm is associated with 
reduced survival in all large CRC series published. Based 
on the two large, unselected patient cohorts in the present 
report, we conclude that nuclear S100A4 is established 
as a biomarker of poor outcome in stage II and III CRC, 
and that further studies to investigate its prognostic role 
in this patient group are not needed.
Even though S100A4 has proven to be a robust prog-
nostic biomarker, its utility in clinical practice is not 
obvious. A negative prognostic factor could be used to 
identify patients that would benefit from additional treat-
ment, for example, to select stage II patients for adjuvant 
Figure 3. Treatment with 5- fluorouracil in CRC cell lines stably transduced with S100A4 shRNA. (A) Immunoblots of total cell lysates from HCT116 
and SW620 cells stably transduced with nontarget shRNA (shNT) or shRNA against S100A4 (shA4- 3) as indicated. Cell viability assay using HCT116 
(B) and SW620 (C) cells stably transduced with nontarget shRNA (shNT) or shRNA against S100A4 (shA4- 3). Cells were treated with seven different 
concentrations of 5- fluorouracil as indicated. Clonogenic survival assay (D) and spheroid assay (E) using HCT116 cells stably transduced with nontarget 
shRNA (shNT) or two different shRNAs against S100A4 (shA4- 1 and shA4- 3). Cells were treated with four different concentrations of 5- fluorouracil 
as indicated. Cell viability, clonogenic survival, and spheroid volume are all displayed as a ratio compared to cells incubated without drug. Bars 
represent ± standard error of the mean. CRC, colorectal cancer.
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chemotherapy. Indeed, S100A4- positive stage II patients 
had a poor prognosis in cohort 1, similar to the results 
in our previous report [6]. In cohort 2, S100A4- positive 
stage II patients randomized to surgery alone had a similar 
outcome as S100A4- negative (Fig. S3D), but there were 
only 10 patients in the S100A4- positive group, suggesting 
that the unexpectedly good outcome compared to the 
other cohorts might have occurred by chance. Nevertheless, 
there was no obvious benefit of adjuvant chemotherapy 
for S100A4- positive stage II patients (Fig. S3E), indicating 
that the adjuvant treatment regimen used was not able 
to improve the inferior outcome associated with strong 
expression of S100A4. However, the study was not suf-
ficiently powered to detect an effect in subgroup analyses, 
and the chemotherapy used is inferior to regimens with 
5- fluorouracil and oxaliplatin, which is the standard of 
care today. Furthermore, there were no indications from 
in vitro experiments that S100A4 is associated with 
increased sensitivity to 5- fluorouracil. Taken together, our 
data indicate that S100A4 is not a useful biomarker for 
the selection of patients for adjuvant fluoropyrimidine- 
based chemotherapy in CRC.
Still, patients with S100A4- positive tumors fare worse 
than S100A4- negative tumors, and the survival difference 
between the groups seems clinically relevant. S100A4- 
positive stage II patients in cohort 1 have an estimated 
5- year relapse- free survival of 66% compared to 84% for 
S100A4- negative patients. The corresponding numbers for 
stage III patients are 46% and 64%, respectively. With 
such inferior relapse- free survival rates, patients with 
S100A4- expressing tumors might benefit from other sys-
temic treatment than fluoropyrimidine- based chemother-
apy. Therapeutic approaches specifically targeting S100A4 
function have been suggested [24, 25], but further devel-
opment might be hampered by the lack of knowledge 
about the biological function of nuclear S100A4 [3, 15]. 
Another strategy could be to target the phenotype induced 
by S100A4 overexpression. S100A4 promotes epithelial–
mesenchymal transition [3], and a mesenchymal phenotype 
is often less sensitive to conventional cancer drugs [26]. 
Design of novel therapies aiming at the mesenchymal, 
stem- cell- like state might thus be beneficial also for the 
S100A4- positive subpopulation of tumor cells.
In conclusion, the present study confirms that nuclear 
S100A4 is a negative prognostic biomarker in patients 
with stage II and III carcinoma of the colon or rectum. 
There was, however, no indication that S100A4 expression 
could be a predictive biomarker for response to 
fluoropyrimidine- based chemotherapy. Further exploring 
the mechanisms involved in S100A4- mediated disease 
progression could hopefully contribute to the development 
of new therapeutic approaches for this patient group, 
which certainly is in need of better treatment options.
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Figure S1. Kaplan-Meier survival curves of relapse-free 
survival from study cohort 1 stratified based on expres-
sion of nuclear S100A4. (A) Data from the complete 
outcome cohort. (B-D) Subgroup analyses in TNM stage 
I, II and II, respectively. (E, F) Subgroup analyses for 
patients with tumors localized in the colon and rectum, 
respectively.
Figure S2. Kaplan-Meier survival curves based on cyto-
plasmic expression of S100A4. (A) Relapse-free survival 
in study cohort 1. (B) Overall survival in study cohort 
1. (C) Relapse-free survival in study cohort 2. (D) Overall 
survival in study cohort 2.
Figure S3. Kaplan-Meier survival curves of relapse-free 
survival for patients with tumors localized in the colon. 
(A) S100A4-negative stage III patients from study cohort 
2 stratified based on randomization arm. (B) S100A4-
positive stage III patients from study cohort 2 stratified 
based on randomization arm. (C) Stage II patients from 
1849© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
S100A4 Expression in Colorectal CancerK. Boye et al.
study cohort 1 stratified based on nuclear S100A4 expres-
sion. (D) Stage II patients from study cohort 2 randomized 
to surgery alone stratified based on nuclear S100A4 expres-
sion. (E) Stage II patients from study cohort 2 randomized 
to adjuvant chemotherapy stratified based on nuclear 
S100A4 expression.
Table S1. Complete scoring results of S100A4 immuno-
histochemistry in study cohort 1.
Table S2. Associations between S100A4 expression and 
clinicopathological parameters in study cohort 1.
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